S. no.

Vaccine Candidate/Country

Developer

Clinical Stage

Expected date of completion

Clinical trial

1

AZD1222 (ChAdOx-1)/United Kingdom

University of Oxford/AstraZeneca

Phase 3: NCT04516746

02-12-20

https://clinicaltrials.gov/ct2/show/NCT04516746?term=astrazeneca&cond=COVID-19&draw=2

2

BNT162b2/ Germany

BioNTech/FosunPharma/Pfizer

Phase 3: NCT04368728

19-04-21

https://clinicaltrials.gov/ct2/show/NCT04368728?term=vaccine&cond=COVID-19&draw=3&rank=12

3

Gam-COVID-Vac and Gam-COVID-Vac-Lyo (Sputnik V)/Russia

Gamaleya Research Institute, Russia

Phase 3: NCT04530396

01-06-21

https://clinicaltrials.gov/ct2/show/NCT04530396?term=vaccine&cond=COVID-19&draw=3

4

Inactivated Coronavirus vaccine/ China

Wuhan Institute of Biological Products/ Beijing Institute of Biological Products/ Sinopharm

Phase 3: NCT04612972

15-07-21

 https://clinicaltrials.gov/ct2/show/NCT04612972

5

Adsorbed COVID-19 (inactivated) Vaccine/China

Sinovac Life Sciences Co., Ltd.

Phase 3: NCT04456595

01-09-21

https://clinicaltrials.gov/ct2/show/NCT04456595?term=vaccine&cond=COVID-19&draw=2

6

 Ad5-nCoV (Recombinant vaccine)/ China

CanSino Biological Inc./Beijing Institute of Biotechnology

Phase 3: NCT04526990

30-12-21

https://clinicaltrials.gov/ct2/show/NCT04526990?term=vaccine&cond=COVID-19&draw=6

7

LNP-encapsulated mRNA-1237/ USA

ModernaTX, Inc. /NIAID

Phase 3: NCT04470427

27-10-22

https://clinicaltrials.gov/ct2/show/NCT04470427?term=vaccine&cond=COVID-19&draw=5

8

NVX- CoV2373/ Matrix-M1™

Novavax, Inc., Emergent BioSolution

Phase 3: NCT04611802

30-12-22

https://clinicaltrials.gov/ct2/show/NCT04611802

9

Ad26.COV2.S, JNJ-78436735 / Belgium

Janssen Pharmaceutical Companies

Phase 3: NCT04505722

10-03-23

https://clinicaltrials.gov/ct2/show/NCT04505722?term=NCT04505722&draw=2&rank=1